SciELO - Scientific Electronic Library Online

 
vol.33 issue6Intravenous iron therapy: how far have we come?Thymoma followed by aplastic anemia: two different responses to immunosuppressive therapy author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Revista Brasileira de Hematologia e Hemoterapia

Print version ISSN 1516-8484

Abstract

BITENCOURT, Roberta; ZALCBERG, Ilana  and  LOURO, Iúri Drumond. Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia. Rev. Bras. Hematol. Hemoter. [online]. 2011, vol.33, n.6, pp. 470-475. ISSN 1516-8484.  http://dx.doi.org/10.5581/1516-8484.20110124.

The development of point mutations in the BCR-ABL kinase domain is the main reason for imatinib resistance in chronic myeloid leukemia. Different detection methods are used in chronic myeloid leukemia monitoring, such as direct sequencing, denaturing high performance liquid chromatography and allele specific polymerase chain reaction. Mutation analysis has become mandatory during patient workup of chronic myeloid leukemia in order for the physician to choose the most suitable tyrosine kinase inhibitor. This article, a review of possible therapies used to overcome imatinib resistance, investigates the current position by searching the PubMed electronic database using the following keywords: imatinib, dasatinib, nilotinib, aurora kinase, SRC kinase, mutation, treatment, drugs and resistance. New tyrosine kinase inhibitors include BCR-ABL kinase selective inhibitors, dual ABL/SRC kinase inhibitors and aurora kinase inhibitors. Awareness of the spectrum of new drugs against mutations, in particular the T315I mutation, makes it possible to properly select the best therapy for each patient.

Keywords : Leukemia, myelogenous, chronic, BCR-ABL positive [drug therapy]; Protein-tyrosine kinases; Drug resistance, neoplasm; Antineoplastic agents [therapeutic use]; Piperazines [therapeutic use]; Pyrimidines [therapeutic use].

        · text in English     · pdf in English